The company operates through three main areas: Pharmaceutical Technologies specializing in sterile and lyophilized injectables and antibiotics; Specialty Pharmacare in Dermatology and Osteoarticular; and Consumer Healthcare with products under the Forté Pharma brand. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through multiple subsidiaries. The company operates four development and production centers across Europe and offers CDMO and CMO services.
Cyborg Score Rationale
As the fifth largest Spanish pharmaceutical company by turnover on the stock market, Reig Jofre holds a strong regional position. The company focuses R&D on development of new indications for known molecules, generics focused on beta lactam and lyophilized injectables, and innovative molecules in partnership with startups. However, limited recent financial data and moderate analyst coverage suggest execution risk.
Top Insights
Strong manufacturing capabilities in specialty injectables and lyophilized antibiotics, high-barrier-to-entry segments
Diversified revenue model combining proprietary pharmaceuticals, CDMO/CMO services, and consumer healthcare reduces single-product dependency
European production footprint (4 centers) provides geographic resilience and proximity to major markets
Fifth-largest Spanish pharma by turnover provides scale advantages while maintaining focused specialization strategy
Named Competitors
Sterile Injectable Manufacuring — Global generic and biosimilar sterile injectables